20:01 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Renal; cardiovascular; hepatic

INDICATION: Renal failure; heart failure; liver failure Mouse studies suggest inhibiting YY1 or its co-repressor FKBP12 could help treat chronic renal, heart and liver failure. In a mouse model of urethral obstruction-induced chronic renal failure,...
19:48 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

Regenerative Patch Technologies' CPCB-RPE1 successfully implanted in AMD patients

Top-line data from the Phase I portion of a Phase I/IIa trial showed that CPCB-RPE1 from Regenerative Patch Technologies Inc. (Glendale, Calif.) was successfully implanted into an eye of four of five patients with non-neovascular...
04:55 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Kadmon reports Phase IIa data for chronic GvDH candidate

Kadmon Holdings Inc. (NYSE:KDMN) reported data from the Phase IIa KD025-208 trial evaluating KD025 to treat steroid-dependent or steroid-refractory chronic graft-versus-host disease (GvHD) in patients who have received an allogeneic bone marrow transplant (BMT) or...
01:22 , Jan 4, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models An allogeneic macaque model of HSCT-associated GvHD could be used to screen for therapies. Transplant of HSCs between pairs of allogeneic cynomolgus macaques that harbored matching major histocompatibility complex (MHC) alleles at...
00:51 , Mar 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Mouse studies suggest topical tacrolimus could help treat lymphedema. In a mouse tail model of lymphedema, a topical formulation of tacrolimus decreased tail swelling and volume, soft tissue thickness, infiltration of inflammatory cells...
20:30 , Jan 13, 2017 |  BC Week In Review  |  Company News

Selten, Vivus deal

Selten granted Vivus exclusive, worldwide rights to develop and commercialize tacrolimus and ascomycin to treat pulmonary arterial hypertension (PAH) and related vascular diseases. Selten had rights to patents covering the drugs from Stanford University (Stanford,...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

Pancreatic islet cells: Phase III data

Top-line data from an open-label, U.S. and Canadian Phase III trial in 48 Type I diabetics with persistent impaired awareness of hypoglycemia who had experienced hypoglycemic events despite physician care showed that 1-3 islet cell...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

Astellas, Leo Pharma deal

Leo Pharma will acquire the global dermatology business of Astellas for EUR675 million ($726.6 million). Astellas’ dermatology portfolio includes Protopic , a topical formulation of the immunosuppressant tacrolimus to treat eczema, and Locoid hydrocortisone butyrate...
01:29 , Nov 12, 2015 |  BC Extra  |  Company News

Leo buys Astellas' dermatology business

Leo Pharma A/S (Ballerup, Denmark) will acquire the global dermatology business of Astellas Pharma Inc. (Tokyo:4503) for EUR 675 million ($726.6 million). Astellas' dermatology portfolio includes Protopic , a topical formulation of immunosuppressant tacrolimus to...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

AMT-110: Phase I/II data

Top-line data from an open-label, French Phase I/II trial in 4 patients ages 20-53 months with Sanfilippo type B syndrome showed that a single administration of intracerebral AMT-110 plus continuous immune suppression therapy with mycophenolate...